Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04891757
Other study ID # FHD-286-C-002
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date June 14, 2021
Est. completion date June 2027

Study information

Verified date April 2024
Source Foghorn Therapeutics Inc.
Contact Foghorn Clinical Trials
Phone 1-888-615-1298
Email clinicaltrials@foghorntx.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This Phase 1, multicenter, open-label, dose escalation study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 administered orally as monotherapy or combination therapy, in subjects with advanced hematologic malignancies.


Description:

This study is primarily intended to evaluate the safety and tolerability of FHD-286 when administered orally as monotherapy or in combination with either LDAC or decitabine to subjects with R/R AML, R/R MDS, and R/R CMML not in blast crisis. In each arm of the study, successive cohorts of participants will receive increasing oral doses of FHD-286 as a single agent or in combination with LDAC or decitabine to determine the RP2D(s) in this population. The data from this study in subjects with advanced hematologic malignancies, including safety, tolerability, PK/PD findings, and antitumor activity, will form the basis for subsequent clinical development of FHD-286.


Recruitment information / eligibility

Status Recruiting
Enrollment 144
Est. completion date June 2027
Est. primary completion date September 2025
Accepts healthy volunteers No
Gender All
Age group 16 Years and older
Eligibility Key Inclusion Criteria: 1. Subject must be =16 years of age. 2. Subject must: - Have a confirmed diagnosis of R/R AML, R/R MDS, or R/R CMML not in blast crisis AND - Have received =4 prior lines of systemic anticancer therapy for their disease under study; subjects who have received >4 prior lines of systemic anticancer therapy for their disease under study must receive Sponsor approval. AND - Be an appropriate candidate for treatment with LDAC (Arm A) or decitabine (Arm B) 3. Subject or their parent or legal guardian (when applicable) must be able to understand and be willing to sign an informed consent and, when applicable, subject must sign an assent form. 4. Subject must be willing and able to comply with scheduled study visits and treatment plans. 5. Subject must be willing to undergo all study procedures unless contraindicated due to medical risk. 6. Subject must have an ECOG PS of =2. 7. Subject must have a life expectancy of =3 months. 8. Subject must have adequate hepatic function. 9. Subject must have adequate renal function. 10. Subject must have a WBC count =20×109/L; treatment with a stable dose of hydroxyurea or other cytoreductive agent (eg, cytarabine) to achieve this count is allowed. 11. Subject must have adequate cardiovascular, respiratory, and immune system function. 12. Subject must agree to abide by dietary and other considerations required during the study. 13. Subject must meet timing requirements with respect to prior therapy and surgery 14. Toxicity related to prior therapy must have returned to Grade =2 by CTCAE by approximately 14 days before the start of study treatment or be deemed irreversible and stable by the Investigator. Exceptions include alopecia, neuropathy, appropriately controlled endocrine toxicities, and other well-controlled stable toxicities with discussion with the Sponsor. 15. Female subjects must be: - postmenopausal; or - permanently sterile, or, if sexually active with male partners, these partners must be azoospermic; or - nonpregnant, nonlactating, and, if sexually active with fertile male partners, having agreed to use a highly effective method of contraception 16. Male subjects must have documented azoospermia or, if fertile and sexually active, must agree to use a highly effective method of contraception with their partners of childbearing potential Key Exclusion Criteria: 1. Subject is unable to provide informed consent and/or to follow protocol requirements. 2. Subject: - Has undergone chimeric antigen receptor T cell therapy or HSCT within 60 days of the first dose of study treatment OR - Has clinically significant GVHD 3. Subject has evidence (or suspicion) of extramedullary involvement, unless approved by Sponsor. 4. Subject has an immediately life-threatening, severe complication(s) of advanced myeloid malignancy, such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation. 5. Subject has other malignancy that may interfere with the diagnosis and/or treatment of advanced hematologic malignancies. 6. Subject has active HBV or HCV infections; Subject has known positive HIV antibody results, or AIDS-related illness. 7. Subject has an active severe infection that requires anti-infective therapy or has an unexplained temperature of >38.5°C during screening visits or on their first day of study treatment. 8. Subject has an uncontrolled intercurrent illness. 9. Subject has QTcF >470 msec or other factors that increase the risk of QTc prolongation or arrhythmic events. 10. Subject has any other medical or psychological condition, deemed by the Investigator to be likely to interfere with a subject's ability to sign informed consent/assent, cooperate, or participate in the study. 11. Subject has known allergies or hypersensitivities to: - All subjects: components of the FHD-286 formulation - Arm A: cytarabine or any of the excipients - Arm B: decitabine or any of the excipients 12. Subject is unable to tolerate the administration of oral medication or has GI dysfunction that would preclude adequate absorption, distribution, metabolism, or excretion of FHD-286. 13. Subject is receiving any other anticancer investigational agents. Investigational agents to treat non-cancer indications may be permitted with Sponsor approval. 14. Exclusion Criteria #14 was removed. 15. Subject is on medications classified as: - Strong CYP3A inhibitors [Exception: Triazole antifungal agents, including those classified as strong CYP3A inhibitors, are permitted.] - Strong CYP3A inducers - Sensitive CYP3A substrates with narrow TIs [Stable doses of immunosuppressant medications that are sensitive CYP3A4 substrates may be permitted with Sponsor approval.] 16. Subject is on medications with narrow TIs that are sensitive P-gp or BCRP substrates and are administered orally or on medications classified as strong inhibitors of P-gp or BCRP. 17. Administration of PPIs should be stopped or switched to another ARA 7 days before administration of FHD-286. 18. Subject is requiring clinically significant or increasing doses of systemic steroid therapy or any other systemic immunosuppressive medication. Local or targeted steroid and immunosuppressive therapies are acceptable. Appropriate steroid replacement to manage endocrine toxicities resulting from prior anticancer systemic therapy is permitted. 19. Subject has undergone any prior treatment with a BRG1/BRM inhibitor. 20. Subject is pregnant or breastfeeding or is planning to become pregnant within 1 year of the start of study treatment.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
FHD-286
FHD-286 administered orally
Low Dose Cytarabine
LDAC administered subcutaneously (SC)
Decitabine
Decitabine administered intravenously

Locations

Country Name City State
United States Dana Farber Cancer Institute Boston Massachusetts
United States City of Hope National Medical Center Duarte California
United States MD Anderson Cancer Center Houston Texas
United States Vanderbilt University Medical Center Nashville Tennessee
United States Memorial Sloan Kettering Cancer Center New York New York

Sponsors (1)

Lead Sponsor Collaborator
Foghorn Therapeutics Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of AEs, dose-limiting toxicities (DLTs), serious AEs (SAEs), AEs leading to discontinuation, and adverse events of special interest (AESIs); safety laboratory assessments Up to 18 months
Secondary AML: Complete remission (CR) rate Up to 18 months
Secondary AML: Duration of CR Up 18 months
Secondary AML: CR + CR with partial hematologic recovery (CRh) rate Up 18 months
Secondary AML: Duration of CR + CRh Up 18 months
Secondary AML: Transfusion independence rate Up 18 months
Secondary AML: Event free survival (EFS) Up 42 months
Secondary AML: Overall survival (OS) Up to 42 months
Secondary MDS: CR rate Up to 18 months
Secondary MDS & CMML: Duration of CR Up to 18 months
Secondary MDS & CMML: Partial remission (PR) rate Up to 18 months
Secondary MDS & CMML: Duration of PR Up to 18 months
Secondary MDS & CMML: CR + PR Up to 18 months
Secondary MDS & CMML: Duration of CR + PR Up to 18 months
Secondary MDS & CMML: Hematologic Improvement rate Up to 18 months
Secondary MDS & CMML: EFS Up to 42 months
Secondary MDS: OS Up to 42 months
Secondary PK parameter: Area under the plasma concentration time curve (AUC) Day 1 and day 8 of cycle 1 (each cycle is 28 days)
Secondary Plasma concentration vs. time profiles Day 1 and day 8 of cycle 1 (each cycle is 28 days)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02890329 - Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia Phase 1
Active, not recruiting NCT04975919 - Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Phase 2
Terminated NCT02882321 - Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT03214562 - Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Active, not recruiting NCT03289910 - Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Phase 2
Completed NCT02756572 - Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms Phase 2
Completed NCT02509546 - 8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Recruiting NCT03683433 - Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation Phase 2
Completed NCT02551718 - High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia N/A
Completed NCT02070458 - Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia Phase 1
Terminated NCT03557970 - JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia Phase 2
Recruiting NCT03661307 - Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome Phase 1/Phase 2
Recruiting NCT03629171 - Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia Phase 2
Recruiting NCT05396859 - Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia Phase 1
Terminated NCT03067571 - Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Phase 2
Completed NCT04146038 - Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease Phase 2
Suspended NCT03128034 - 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia Phase 1/Phase 2
Active, not recruiting NCT04207190 - Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT04047641 - Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Phase 1/Phase 2
Withdrawn NCT04493099 - Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML Phase 1/Phase 2